Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
Open Access
- 13 June 2014
- journal article
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 12 (1) , 27
Abstract
Background: In recent years, China has experienced tremendous growth in its pharmaceutical industry. Both the Chinese government and private investors are motivated to invest into pharmaceutical research and development (R&D). However, studies regarding the different behaviors of public and private investment in pharmaceutical R&D are scarce. Therefore, this paper aims to investigate the current situation of public funding and private investment into Chinese pharmaceutical R&D. Methods: The primary data used in the research were obtained from the China High-tech Industry Statistics Yearbook (2002–2012) and China Statistical Yearbook of Science and Technology (2002–2012). We analyzed public funding and private investment in five aspects: total investment in the industry, funding sources of the whole industry, differences between provinces, difference in subsectors, and private equity/venture capital investment. Results: The vast majority of R&D investment was from private sources. There is a significantly positive correlation between public funding and private investment in different provinces of China. However, public funding was likely to be invested into less developed provinces with abundant natural herbal resources. Compared with the chemical medicine subsector, traditional Chinese medicine and biopharmaceutical subsectors obtained more public funding. Further, the effect of the government was focused on private equity and venture capital investment although private fund is the mainstream of this type of investment. Conclusions: Public funding and private investment play different but complementary roles in pharmaceutical R&D in China. While being less than private investment, public funding shows its significance in R&D investment. With rapid growth of the industry, the pharmaceutical R&D investment in China is expected to increase steadily from both public and private sources.Keywords
This publication has 13 references indexed in Scilit:
- China spurs pharma innovationNature Reviews Drug Discovery, 2010
- An Empirical Analysis of the Relationship Between Capital Acquisition and Bankruptcy LawsJournal of Small Business Management, 2009
- Enforcing pharmaceutical and biotech patent rights in ChinaNature Biotechnology, 2008
- How Venture Capital Shapes Emerging Bio-clusters—A Cross-country ComparisonEuropean Planning Studies, 2008
- Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry?The Journal of Law and Economics, 2007
- Do Public Subsidies Complement Business R&D? A Meta‐Analysis of the Econometric EvidenceKyklos, 2004
- The impact of public R&D expenditure on business R&D*Economics of Innovation and New Technology, 2003
- Is public R&D a complement or substitute for private R&D? A review of the econometric evidenceResearch Policy, 2000
- Endogenous Technological ChangeJournal of Political Economy, 1990
- The Effect of Government Funding on Private Industrial Research and Development: A Re-AssessmentThe Journal of Industrial Economics, 1987